Sévoflurane : interactions médicamenteuses

L'association de l'alcool avec des médicaments sédatifs (opioïdes, benzodiazépines, somnifères, myorelaxants) peut provoquer une somnolence dangereuse, un ralentissement de la respiration et un surdosage. (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (notice Alprazolam, Mises en garde et précautions)

Table 5: Amiodarone Drug Interactions Concomitant Drug Class/Name Examples Clinical Comment QT Prolonging Drugs class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents Increased risk of Torsade de Pointes. (notice Amiodarone, Interactions médicamenteuses)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (notice Azélastine et fluticasone, Mises en garde et précautions)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

•patients with a known hypersensitivity to bupivacaine or to any local anesthetic agent of the amide-type or to other components of MARCAINE / MARCAINE WITH EPINEPHRINE. (notice Bupivacaïne, Contre-indications)

• patients with a known hypersensitivity to bupivacaine or to any local anesthetic agent of the amide-type or to other components of MARCAINE / MARCAINE WITH EPINEPHRINE. (notice Bupivacaïne et adrénaline, Contre-indications)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (notice Carbamazépine, Interactions médicamenteuses)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (notice Carbinoxamine, Mises en garde et précautions)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (notice Cétirizine, Mises en garde et précautions)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Chlordiazépoxide, Mises en garde)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Chlordiazépoxide et clidinium, Mises en garde)

To avoid intravascular injection, aspiration should be performed before the anesthetic solution is injected. (notice Chloroprocaïne, Mises en garde)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (notice Ciprofloxacine, Interactions médicamenteuses)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Clobazam, Mises en garde et précautions)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Clonazépam, Mises en garde)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (notice Clonidine, Mises en garde et précautions)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Clorazépate, Mises en garde)

NUMBRINO is contraindicated in: patients with a known history of hypersensitivity to cocaine hydrochloride, other ester-based local anesthetics, or any other component of the nasal solution [see Warnings and Precautions ( 5.5 )] . (notice Cocaïne, Contre-indications)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (notice Cyclobenzaprine, Interactions médicamenteuses)

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance… (notice Darunavir, Contre-indications)

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is contraindicated in patients receiving certain co-administered drugs for which altered plasma… (notice Darunavir et cobicistat, Contre-indications)

Known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics. (notice Sévoflurane, Contre-indications)

Intervention Avoid use of Focalin XR in patients being treated with anesthetics on the day of surgery. (notice Dexméthylphénidate, Interactions médicamenteuses)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Diazépam, Mises en garde)

Use as a Local Anesthetic Because of the risk of local necrosis, this drug should not be used as a local anesthetic. (notice Diphénhydramine, Contre-indications)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (notice Diphénoxylate et atropine, Contre-indications)

Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 ) (notice Doxylamine et pyridoxine, Mises en garde et précautions)

Other risk factors may include age over 65 years, alcohol abuse, and use of agents such as benzodiazepines, volatile anesthetics, and IV opiates. (notice Dropéridol, Mise en garde encadrée)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

…Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly dependent on CYP3A for clearance and for which… (notice Elvitégravir, cobicistat, emtricitabine et ténofovir, Contre-indications)

Due to the use of lidocaine HCl as a diluent, INVANZ administered intramuscularly is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type. (notice Ertapénem, Contre-indications)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Estazolam, Mises en garde)

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (notice Eszopiclone, Mises en garde et précautions)

Known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics. (notice Sévoflurane, Contre-indications)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

…Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (notice Fosamprénavir, Contre-indications)

• Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. (notice Gabapentine, Mises en garde et précautions)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (notice Hydroxyzine, Précautions)

Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (notice Imipramine, Interactions médicamenteuses)

Known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics. (notice Sévoflurane, Contre-indications)

Known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics. (notice Sévoflurane, Contre-indications)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (notice Kétoconazole, Contre-indications)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (notice Lévocétirizine, Mises en garde et précautions)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

CONTRAINDICATIONS Lidocaine HCl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. (notice Lidocaïne, Contre-indications)

FLAVALTA is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any components of the injectable formulations. (notice Lidocaïne et adrénaline, Contre-indications)

Oraqix is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any other component of the product. (notice Lidocaïne et prilocaïne, Contre-indications)

…Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavir plasma concentrations… (notice Lopinavir et ritonavir, Contre-indications)

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (notice Lorazépam, Mises en garde et précautions)

CONTRAINDICATIONS: Mepivacaine is contraindicated in patients with a known hypersensitivity to it or to any local anesthetic agent of the amide-type or to other components of solutions of mepivacaine. (notice Mépivacaïne, Contre-indications)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (notice Métaxalone, Mises en garde et précautions)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics. (notice Sévoflurane, Contre-indications)

Intervention Avoid use of methylphenidate extended-release orally disintegrating tablets in patients being treated with anesthetics on the day of surgery. (notice Méthylphénidate, Interactions médicamenteuses)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (notice Midazolam, Mise en garde encadrée)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (notice Nalméfène, Mises en garde et précautions)

The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (notice Néomycine, Mise en garde encadrée)

…(selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin • Vasopressin receptor antagonists: tolvaptan ➢ Drugs that… (notice Nirmatrelvir et ritonavir, Contre-indications)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (notice Olopatadine, Mises en garde et précautions)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (notice Olopatadine et mométasone, Mises en garde et précautions)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Oxazépam, Mises en garde)

• Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. (notice Oxybate de sodium, Mise en garde encadrée)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (notice Phénelzine, Contre-indications)

CNS depressants: Closely monitor for sedation and respiratory depression. (notice Phénobarbital, Interactions médicamenteuses)

• Respiratory Depression : May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. (notice Prégabaline, Mises en garde et précautions)

CONTRAINDICATIONS Prilocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type and in those rare patients with congenital or idiopathic methemoglobinemia. (notice Prilocaïne et adrénaline, Contre-indications)

Idiosyncratic Hypersensitivity: In patients sensitive to procaine or other ester-type local anesthetics, cross sensitivity to PA is unlikely. (notice Procaïnamide, Contre-indications)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics. (notice Sévoflurane, Contre-indications)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (notice Ritonavir, Mise en garde encadrée)

NAROPIN is contraindicated in patients with a known hypersensitivity to ropivacaine or to any local anesthetic agent of the amide type. (notice Ropivacaïne, Contre-indications)

• When a healthy appearing pediatric patient develops cardiac arrest within minutes after administration of QUELICIN, not felt to be due to inadequate ventilation, oxygenation or anesthetic overdose, immediate treatment for hyperkalemia should be instituted. (notice Suxaméthonium, Mise en garde encadrée)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (notice Témazépam, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

Risk of Respiratory Depression Sevoflurane may cause respiratory depression, which may be augmented by opioid premedication or other agents causing respiratory depression. (notice Sévoflurane, Mises en garde)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (notice Triazolam, Mises en garde et précautions)

When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression. (notice Vérapamil, Interactions médicamenteuses)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (notice Zaléplone, Mises en garde)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (notice Zolpidem, Mises en garde et précautions)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (notice Allopurinol, Mises en garde et précautions)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Concurrent use with general anesthetics may result in arrhythmias. (notice Amfépramone, Interactions médicamenteuses)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (notice Aminophylline, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

When used to supplement alfentanil-N 2 O anesthesia, sevoflurane and isoflurane equally potentiate neuromuscular block induced with pancuronium, vecuronium or atracurium. (notice Sévoflurane, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. (notice Sévoflurane, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

PRECAUTIONS Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication. (notice Benzonatate, Précautions)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (notice Bictégravir, emtricitabine et ténofovir alafénamide, Interactions médicamenteuses)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (notice Sévoflurane, Interactions médicamenteuses)

Use with CNS depressants may result in an additive or potentiating effect. (notice Brimonidine, Interactions médicamenteuses)

Use with CNS depressants may result in an additive or potentiating effect. (notice Brimonidine et timolol, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (notice Buspirone, Interactions médicamenteuses)

Butalbital and acetaminophen may enhance the effects of:other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (notice Butalbital et paracétamol, Interactions médicamenteuses)

Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (notice Butalbital, aspirine et caféine, Interactions médicamenteuses)

Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (notice Butalbital, paracétamol et caféine, Interactions médicamenteuses)

Other CNS depressants, including alcohol, could potentiate the somnolence and sedation effect of EPIDIOLEX. (notice Cannabidiol (sur ordonnance), Mises en garde et précautions)

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. (notice Sévoflurane, Interactions médicamenteuses)

Anesthesia If treatment with COREG is to be continued perioperatively, particular care should be taken when anesthetic agents that depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used [see Overdosage (10) ]. (notice Carvédilol, Interactions médicamenteuses)

Concomitant use with other CNS depressants or alcohol may have additive effects. (notice Cénobamate, Mises en garde et précautions)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. (notice Sévoflurane, Interactions médicamenteuses)

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. (notice Sévoflurane, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. (notice Sévoflurane, Interactions médicamenteuses)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (notice Daridorexant, Mises en garde et précautions)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Anesthetics, Sedatives, Hypnotics, Opioids: Enhancement of pharmacodynamic effects. (notice Dexmédétomidine, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (notice Dronabinol, Mises en garde et précautions)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Rocuronium C linical Impact: Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction. (notice Éphédrine, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (notice Flibansérine, Mises en garde et précautions)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Benzodiazepines and Opioids Benzodiazepines and opioids would be expected to decrease the MAC of sevoflurane in the same manner as with other inhalational anesthetics. (notice Sévoflurane, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Moreover, it should be remembered that reduced amounts of anesthetics or central nervous system depressants may be necessary. (notice Fluphénazine, Précautions)

The possibility of these phenomena occurring in man should be considered if aminoglycosides are administered by any route to patients receiving anesthetics, or to patients receiving neuro-muscular blocking agents, such as succinylcholine, tubocurarine, or decamethonium, or in patients receiving massive transfusions of citrate-anticoagulated blood. (notice Gentamicine, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider the potential for additive sedative effects with CNS depressant drugs. (notice Guanfacine, Mises en garde et précautions)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

• Local anesthetics: Hyaluronidase hastens onset and shortens duration of effect, increases incidence of systemic reactions ( 7.3 ) (notice Hyaluronidase, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. (notice Sévoflurane, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (notice Sévoflurane, Interactions médicamenteuses)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (notice Lemborexant, Mises en garde et précautions)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (notice Sévoflurane, Interactions médicamenteuses)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (notice Lofexidine, Mises en garde et précautions)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Additive Effects Since the effects of meprobamate and alcohol or meprobamate and other CNS depressants or psychotropic drugs may be additive,appropriate caution should be exercised with patients who take more than one of these agents simultaneously. (notice Méprobamate, Mises en garde)

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. (notice Sévoflurane, Interactions médicamenteuses)

Patients may require reduced doses of anesthetics when on methyldopa. (notice Méthyldopa, Interactions médicamenteuses)

Anesthetics Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate. (notice Méthylergométrine, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (notice Métirosine, Interactions médicamenteuses)

Concomitant use of central nervous system (CNS) depressants or drugs associated with EPS may increase this effect (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics). (notice Métoclopramide, Mises en garde et précautions)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

DRUG INTERACTIONS When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general - exaggeration of the hypotension induced by general anesthetics (see WARNINGS , Major Surgery ). (notice Nadolol, Interactions médicamenteuses)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (notice Naloxone, Mises en garde et précautions)

…malformation, central nervous system tumor or infection, or metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia) excessive use of alcohol or sedatives, addiction to cocaine or stimulants, or withdrawal from sedatives patients with diabetes treated with insulin and/or oral diabetic medications (sulfonylureas and meglitinides)… (notice Naltrexone et bupropion, Mises en garde et précautions)

If BYSTOLIC is to be continued perioperatively, monitor patients closely when anesthetic agents which depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used. (notice Nébivolol, Mises en garde et précautions)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. (notice Sévoflurane, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when FYCOMPA is used with other drugs with sedative properties because of potential additive effects. (notice Pérampanel, Mises en garde et précautions)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

The concomitant use of alcohol or central nervous system (CNS) depressant drugs with phentermine and topiramate extended-release capsules may potentiate CNS depression or other centrally mediated effects of these agents, such as dizziness, cognitive adverse reactions, drowsiness, light-headedness, impaired coordination, and somnolence. (notice Phentermine et topiramate, Mises en garde et précautions)

Lidocaine and Epinephrine When OraVerse was administered as an intraoral submucosal injection 30 minutes after injection of a local anesthetic, 2% lidocaine HCl with 1:100,000 epinephrine, the lidocaine concentration increased immediately after OraVerse intraoral injection. (notice Phentolamine, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (notice Rameltéon, Mises en garde et précautions)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (notice Sévoflurane, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. (notice Sévoflurane, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (notice Sévoflurane, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

CNS Depressant Effects and Daytime Impairment: Risk of impaired alertness and motor coordination, including impaired driving; risk increases with dose; caution patients taking 20 mg against next-day driving and other activities requiring complete mental alertness ( 5.1 ). (notice Suvorexant, Mises en garde et précautions)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (notice Sévoflurane, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (notice Théophylline, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

As in the case of other CNS-acting drugs, patients receiving thiothixene should be cautioned about the possible additive effects (which may include hypotension) with CNS depressants and with alcohol. (notice Tiotixène, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. (notice Sévoflurane, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Because of the potential of topiramate to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse reactions, topiramate extended-release capsules should be used with extreme caution if used in combination with alcohol and other CNS depressants. (notice Topiramate, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Neuromuscular Blocking Agents As is the case with other volatile anesthetics, sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarizing muscle relaxants. (notice Sévoflurane, Interactions médicamenteuses)

The hypotensive effect of certain inhalation anesthetics may be enhanced by ACE inhibitors including trandolapril. (notice Trandolapril, Interactions médicamenteuses)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (notice Sévoflurane, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

The effects of the following drugs may be potentiated when given together with triamterene: antihypertensive medication, other diuretics, preanesthetic and anesthetic agents, skeletal muscle relaxants (non-depolarizing). (notice Triamtérène, Interactions médicamenteuses)

If agents such as sedatives, narcotics, anesthetics, tranquilizers or alcohol are used either simultaneously or successively with the drug, the possibility of an undesirable additive depressant effect should be considered. (notice Trifluopérazine, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (notice Triméthobenzamide, Mises en garde et précautions)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

To reduce the risk of infusion reactions, administer Vancomycin Injection over a period of 60 minutes or greater and also prior to intravenous anesthetic agents. (notice Vancomycine, Mises en garde et précautions)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

When used to supplement alfentanil-N 2 O anesthesia, sevoflurane and isoflurane equally potentiate neuromuscular block induced with pancuronium, vecuronium or atracurium. (notice Sévoflurane, Interactions médicamenteuses)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (notice Sévoflurane, Mises en garde)

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when ZONISADE is used with other drugs with sedative properties because of potential additive effects. (notice Zonisamide, Mises en garde et précautions)

Particular care should be taken when using anesthetic agents which depress the myocardium, such as ether, cyclopropane, and trichloroethylene (see Warnings, Major surgery ). (notice Bétaxolol, Interactions médicamenteuses)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (notice Bupropion, Mises en garde et précautions)

Application-Associated Pain Even following use of a local anesthetic prior to administration of QUTENZA, patients may experience substantial procedural pain and burning upon application of QUTENZA and following removal of QUTENZA. (notice Capsaïcine, Mises en garde et précautions)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (notice Dexamfétamine, Interactions médicamenteuses)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (notice Doxapram, Mises en garde)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (notice Époétine alfa, Mises en garde et précautions)

Therefore, ambulatory patients should be warned about activities requiring alertness (e.g., operating vehicles or machinery) and about concomitant use of alcohol and other CNS depressants. (notice Loxapine, Mises en garde)

The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (notice Naltrexone, Mises en garde et précautions)

General Anesthetics – Little is known about the potential for interaction between nefazodone and general anesthetics; therefore, prior to elective surgery, nefazodone hydrochloride should be discontinued for as long as clinically feasible. (notice Néfazodone, Interactions médicamenteuses)

Drug Interactions The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics. (notice Nitroprussiate de sodium, Interactions médicamenteuses)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (notice Prazosine, Interactions médicamenteuses)

Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. (notice Sévoflurane, Interactions médicamenteuses)

Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all. (notice Pyridostigmine, Interactions médicamenteuses)

Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. (notice Sévoflurane, Interactions médicamenteuses)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use with caution when midazolam or triazolam is concomitantly administered with SUNLENCA 7.4 Drugs without Clinically Significant Interactions with SUNLENCA Based on drug interaction studies conducted with SUNLENCA, no clinically significant drug interactions have been observed with:… (notice Lénacapavir, Interactions médicamenteuses)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (notice Montélukast, Interactions médicamenteuses)